Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 5Leukemia, Myeloid, Acute 4Leukemia, Myelomonocytic, Chronic 3Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Cytopenia 2Anemia, Refractory, with Excess of Blasts 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Splenomegaly 1Polycythemia Vera 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Anemia, Refractory 1Anemia 1

Interventions

Surveys and Questionnaires 2Ritonavir 1Quality of Life 1ON 01910 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Splenomegaly × ON 01910 × Other hematologic neoplasm × Clear all
NCT02730884 2020-08-07

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 6 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Splenomegaly, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡